Trinity Biotech Long Term Debt 2010-2024 | TRIB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Trinity Biotech long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Trinity Biotech long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$200B
Stryker (SYK)	$141B
Boston Scientific (BSX)	$128B
Medtronic (MDT)	$113B
EssilorLuxottica (ESLOY)	$112.7B
Lonza Group Ag (LZAGY)	$45.3B
Haleon (HLN)	$43.5B
GE HealthCare Technologies (GEHC)	$40.4B
ResMed (RMD)	$36.5B
Terumo (TRUMY)	$30.3B
Koninklijke Philips (PHG)	$25.9B
Zimmer Biomet Holdings (ZBH)	$21.6B
Baxter (BAX)	$18.4B
Insulet (PODD)	$17.2B
Smith & Nephew SNATS (SNN)	$10.8B
Bio-Rad Laboratories (BIO)	$10.4B
BellRing Brands (BRBR)	$8.9B
Demant (WILYY)	$8.4B
Lantheus Holdings (LNTH)	$6.1B
Haemonetics (HAE)	$4.4B
ICU Medical (ICUI)	$4.4B
TG Therapeutics (TGTX)	$4.3B
Prestige Consumer Healthcare (PBH)	$4B
Envista Holdings (NVST)	$3.7B
Perrigo (PRGO)	$3.7B
Neogen (NEOG)	$3.4B
Agios Pharmaceuticals (AGIO)	$3.1B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.9B
QuidelOrtho (QDEL)	$2.6B